Activation of Cu(II)-reducing ability of monoamine neurotransmitters triggered by amyloid-β fibrillization
Archives of Biochemistry and Biophysics · 2026
DOI: 10.1016/j.abb.2026.111013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026. Verfasst von Takumi Kurihara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, International University of Health and Welfare, Kitakanemaru 2600-1, Otawara, Tochigi, 324-8501, Japan. Hauptthemen laut MEDLINE: Copper, Amyloid beta-Peptides, Serotonin, Dopamine. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The reduction of Cu(II) to Cu(I) in oxidative extracellular environments contributes to oxidative stress because the reoxidation of Cu(I) back to Cu(II) generates reactive oxygen species. Monoamine neurotransmitters such as serotonin (5-HT) and dopamine (DA) possess Cu(II)-reducing ability and coexist with copper ions near the synapse, suggesting that they may serve as potential mediators of oxidative stress. The neurotoxicity of aggregated amyloid-β peptide (Aβ) observed in the brains of Alzheimer's disease patients is thought to arise from oxidative stress induced by complex formation of Aβ with redox-active metal ions. However, the absence of apparent Cu(II)-reducing activity in Aβ suggests the involvement of other reducing agents in the generation of oxidative stress. In this study, we examined the effects of Aβ on the redox reactions between copper and monoamine neurotransmitters 5-HT and DA. The Cu(II)-reducing activities of both neurotransmitters, together with the accompanying production of hydrogen peroxide, were inhibited by either unfibrillized Aβ1-40 or non-amyloidogenic Aβ1-16, whereas fibrillized Aβ1-40 enhanced them. Canonical small-molecule Cu(II) ligands, such as l-histidine, diminished these activities, whereas Cu(I) chelators exerted an enhancing effect. These findings suggest that the activation of monoamine-mediated copper reduction by fibrillized Aβ1-40 may be attributable to the Cu(I)-binding capability that is absent in the monomeric form. This study provides a partial mechanistic basis for the causal link between Aβ aggregation and the onset of Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, International University of Health and Welfare, Kitakanemaru 2600-1, Otawara, Tochigi, 324-8501, Japan.
- Department of Pharmaceutical Sciences, International University of Health and Welfare, Kitakanemaru 2600-1, Otawara, Tochigi, 324-8501, Japan. Electronic address: tmiura@ihwg.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kurihara, T., Aoyagi, R., Kitase, S., Kuroda, S., Kaneko, M., & Miura, T. (2026). Activation of Cu(II)-reducing ability of monoamine neurotransmitters triggered by amyloid-β fibrillization. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2026.111013
Vancouver
Kurihara T, Aoyagi R, Kitase S, Kuroda S, Kaneko M, Miura T. Activation of Cu(II)-reducing ability of monoamine neurotransmitters triggered by amyloid-β fibrillization. Archives of Biochemistry and Biophysics. 2026. doi:10.1016/j.abb.2026.111013
BibTeX
@article{Kurihara2026,
author = {Kurihara, Takumi and Aoyagi, Risa and Kitase, Saki and Kuroda, Saki and Kaneko, Minami and Miura, Takashi},
title = {Activation of Cu(II)-reducing ability of monoamine neurotransmitters triggered by amyloid-β fibrillization},
journal = {Archives of Biochemistry and Biophysics},
year = {2026},
doi = {10.1016/j.abb.2026.111013}
}
EUVIMED